Loading...
•
Jun 30, 2021
Edwards Lifesciences Q2 2021 Earnings Report
Edwards Lifesciences reported strong second-quarter results, driven by a rebound in sales and growth across all product groups.
Key Takeaways
Edwards Lifesciences reported a strong second quarter with sales up 49% to $1.4 billion and underlying sales growth of 44%. TAVR sales exceeded expectations, growing 52%. The company raised its full-year sales guidance to $5.2 to $5.4 billion and adjusted EPS guidance to the high end of the previous $2.07 to $2.27 range.
Sales rebounded and grew 49 percent to $1.4 billion; underlying sales grew 44 percent
TAVR sales exceeded expectations and grew 52 percent; underlying sales grew 48 percent
EPS was $0.78; adjusted EPS was $0.64
Continued progress on five pivotal trials in TMTT
Revenue by Segment
Revenue by Geographic Location
Forward Guidance
The company now expects full year 2021 sales of $5.2 to $5.4 billion versus previous guidance of $4.9 to $5.3 billion. The company is raising full year 2021 adjusted earnings per share guidance to the high end of the previous $2.07 to $2.27 range. For the third quarter of 2021, the company projects sales to be between $1.29 and $1.37 billion, and adjusted EPS of $0.50 to $0.56.
Revenue & Expenses
Visualization of income flow from segment revenue to net income
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...